JI Han-bin1, HE Qiu-xia1, GONG Shi-lin1, WANG Wen-jing1, LONG Fei-yan1, YANG Chen-chen1, YU Wen-hai2, HUANG Fen1
1. Kunming University of Science and Technology Medical School, Kunming 650500, China; 2. Institute of Medical Biology,Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650038,China
Abstract：To investigate the effect of zinc finger antiviral protein (ZAP) on replication of hepatitis E virus (HEV) in vivo, an eukaryotic expression vector of ZAP were constructed and injected into BALB/c mice with pre-infected by HEV. Using 18T-ZAP as template, the sequence of ZAP gene was amplified by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and cloned into eukaryotic expression vector pcDNA3.1. BALB/c mice were injected with different concentrations of pcDNA3.1-ZAP via tail vein and then inoculated with HEV. Quantitative Real-Time PCR (RT-qPCR) and immunohistochemistry were used to identify the effect of ZAP on HEV replication. The eukaryotic expression plasmid pcDNA3.1-ZAP was successfully constructed by double digestion and sequencing. HEV replication was significantly inhibited in mice injected with ZAP. This study shows that ZAP can inhibit the replication of HEV in vivo and it provides a basis for the prevention and treatment of HEV.
纪汉斌, 何秋霞, 龚石林, 王文静, 龙飞燕, 杨臣臣, 禹文海, 黄芬. 锌指抗病毒蛋白抑制HEV体内复制[J]. 中国人兽共患病学报, 2020, 36(6): 456-460.
JI Han-bin, HE Qiu-xia, GONG Shi-lin, WANG Wen-jing, LONG Fei-yan, YANG Chen-chen, YU Wen-hai, HUANG Fen. ZAP inhibits the replication of HEV in vivo. Chinese Journal of Zoonoses, 2020, 36(6): 456-460.
[1] Aggarwal R, Krawczynski K.Hepatitis E: an overview and recent advances in clinical and laboratory research[J]. J Gastroenterol Hepatol, 2000,15:9-20. DOI:10.1046/j. 1440-1746.2000.02006.x [2] Aggarwal R, Jameel S.Hepatitis E[J]. Hepatology,2011,54:2218-2226. DOI:10.1002/hep.24674 [3] Emerson SU, Purcell RH.Hepatitis E virus[J]. Rev Med Virol, 2003,13:145-154. DOI:10.1002/rmv.384 [4] Himmelsbach K, Bender D, Hildt E.Life cycle and morphogenesis of the hepatitis E virus[J]. Emerg Microbes Infect, 2018,7:196. DOI:10.1038/s41426-018-0198-7 [5] Rein DB, Stevens GA, Theaker J, et al.The global burden of hepatitis E virus genotypes 1 and 2 in 2005[J]. Hepatology, 2012,55:988-997. DOI:10.1002/hep.25505 [6] Jia Z, Yi Y, Liu J, et al.Epidemiology of hepatitis E virus in China: results from the third national viral hepatitis prevalence survey, 2005-2006[J]. PLoS One, 2014,9: e110837. DOI:10.1371/journal.pone.0110837 [7] Zhou S, Liu R, Baroudy BM, et al.The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA[J]. Virology, 2003,310:333-342. DOI:10.1016/s0042-6822(03)00152-1 [8] Pischke S, Hardtke S, Bode U, et al.Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience[J]. Liver Int, 2013,33:722-726. DOI:10.1111/liv.12114 [9] Kamar N, Izopet J, Tripon S, et al.Ribavirin for chronic hepatitis E virus infection in transplant recipients[J]. N Engl J Med, 2014,370:1111-1120. DOI:10.1056/ NEJMoa1215246 [10] Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients[J]. Gastroenterology,2014, 147:1008-1011 e7; quiz e15-6. DOI:10.1053/j.gastro. 2014.08.040 [11] 李文莉, 吴茂盛, 黄育波, 等. α-干扰素治疗慢性乙型肝炎患者外周血单个核细胞TLR4表达和血清Th1/Th2型细胞因子的变化[J]. 实用肝脏病杂志, 2012,15:315-317 [12] Yao G, Ji Y, Yang M, et al.Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients[J]. Chin Med J (Engl), 1998,111:922-926 [13] Zhang F, Qi Y, Harrison TJ, et al.Hepatitis E genotype 4 virus from feces of monkeys infected experimentally can be cultured in PLC/PRF/5 cells and upregulate host interferon-inducible genes[J]. J Med Virol,2014,86: 1736-1744. DOI 10.1002/jmv.24014 [14] Kamar N, Abravanel F, Garrouste C, et al.Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient[J]. Nephrol Dial Transplant, 2010,25:2792-2795. DOI:10.1093/ ndt/gfq282 [15] Kamar N, Rostaing L, Abravanel F, et al.Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation[J]. Clin Infect Dis, 2010,50:e30-e33. DOI:10.1086/650488 [16] Haagsma EB, Riezebos-Brilman A, van den Berg AP, et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b[J]. Liver Transpl, 2010,16:474-477. DOI:10.1002/lt.22014 [17] Kamar N, Bendall R, Legrand-Abravanel F, et al.Hepatitis E[J]. Lancet,2012,379:2477-2488. DOI:10.1016/ s0140-6736(11)61849-7 [18] Debing Y, Emerson SU, Wang Y, et al.Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon[J]. Antimicrob Agents Chemother, 2014,58:267-273. DOI:10.1128/aac.01795-13 [19] Akira S, Uematsu S, Takeuchi O.Pathogen recognition and innate immunity[J]. Cell, 2006,124:783-801. DOI:10.1016/j.cell.2006.02.015 [20] Ishii KJ, Koyama S, Nakagawa A, et al.Host innate immune receptors and beyond: making sense of microbial infections[J]. Cell Host Microbe,2008,3:352-363. DOI:10.1016/j.chom.2008.05.003 [21] Takeuchi O, Akira S.Pattern recognition receptors and inflammation[J]. Cell, 2010,140:805-820. DOI:10.1016/j.cell.2010.01.022 [22] Jensen S, Thomsen AR.Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion[J]. J Virol,2012,86:2900-2910. DOI:10.1128/jvi.05738-11 [23] Thompson MR, Kaminski JJ, Kurt-Jones EA, et al.Pattern recognition receptors and the innate immune response to viral infection[J]. Viruses,2011,3:920-940. DOI:10.3390/v3060920 [24] Randall RE, Goodbourn S.Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures[J]. J Gen Virol,2008,89:1-47. DOI:10.1099/vir.0.83391-0 [25] Perez O, Hope TJ.Cellular restriction factors affecting the early stages of HIV replication[J]. Curr HIV/AIDS Rep,2006,3:20-25. DOI:10.1007/s11904-006-0004-3 [26] Merindol N, Berthoux L.Restriction Factors in HIV-1 Disease Progression[J]. Curr HIV Res,2015,13:448-461. DOI:10.2174/1570162x13666150608104412 [27] 朱益平. 锌指抗病毒蛋白(ZAP)抑制HIV-1复制的分子机制[D].北京:中国科学院研究生院, 2010. [28] Kai K, Ikeda H, Yuasa Y, et al.Mouse strain resistant to N-, B-, and NB-tropic murine leukemia viruses[J]. J Virol, 1976, 20:436-440 [29] Stremlau M, Owens CM, Perron MJ, et al.The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys[J]. Nature,2004,427:848-853. DOI:10.1038/nature02343 [30] Hilberg F, Stocking C, Ostertag W, et al.Functional analysis of a retroviral host-range mutant: altered long terminal repeat sequences allow expression in embryonal carcinoma cells[J]. Proc Natl Acad Sci U S A,1987, 84:5232-5236. DOI:10.1073/pnas.84.15.5232 [31] Guo X, Carroll JW, Macdonald MR, et al.The zinc finger antiviral protein directly binds to specific viral mRNAs through the CCCH zinc finger motifs[J]. J Virol,2004, 78:12781-12787. DOI:10.1128/jvi.78.23. 12781-12787.2004 [32] Mao R, Nie H, Cai D, et al.Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein[J]. PLoS Pathog, 2013,9:e1003494. DOI:10.1371/journal.ppat. 1003494 [33] Gao G, Guo X, Goff SP.Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein[J]. Science, 2002,297:1703-1706. DOI:10.1126/science. 1074276 [34] Bick MJ, Carroll JW, Gao G, et al.Expression of the zinc-finger antiviral protein inhibits alphavirus replication[J]. J Virol,2003,77:11555-11562. DOI:10.1128/jvi.77.21.11555-11562.2003 [35] Muller S, Moller P, Bick MJ, et al.Inhibition of filovirus replication by the zinc finger antiviral protein[J]. J Virol,2007,81:2391-2400. DOI:10.1128/jvi.01601-06 [36] Lai WS, Carballo E, Thorn JM, et al.Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA[J]. J Biol Chem, 2000,275:17827-17837. DOI:10.1074/jbc.M001696200 [37] Carballo E, Lai WS, Blackshear PJ.Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability[J]. Blood, 2000,95:1891-1899 [38] Zhu FC, Zhang J, Zhang XF, et al.Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial[J]. Lancet,2010,376:895-902. DOI:10.1016/s0140-6736(10)61030-6 [39] Wu T, Zhu FC, Huang SJ, et al.Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis[J]. Hepatology,2012,55:2038. DOI:10.1002/hep.25522 [40] Todt D, Gisa A, Radonic A, et al.In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome[J]. Gut,2016,65:1733-1743. DOI:10.1136/ gutjnl-2015-311000 [41] Gouttenoire J, Szkolnicka D, Moradpour D.Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing[J]. Gut, 2016,65:1583-1584. DOI:10.1136/ gutjnl-2016-312040
2020, Vol. 36 
